Abbott Laboratories ABT recently announced FDA approval for its latest version of MitraClip heart valve repair device to treat mitral regurgitation (MR). With the approval for the fourth-generation ...

- CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology - MitraClip is a first-of-its-kind ...

Transcatheter mitral valve repair using the MitraClip can be performed safely with a high rate of success in high-risk patients with degenerative or functional mitral regurgitation (MR), according to ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter mitral valve repair improved outcomes and symptoms in patients with moderate to severe mitral ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Transcatheter mitral valve repair for patients with HF and severe secondary mitral regurgitation ...

The Centers for Medicare & Medicaid Services (CMS) is widely expected to show some love for functional mitral valve disease on February 14, 2020. That’s when CMS is due to release its updated proposal ...

A study from Abbott found that employing its cardiac valve repair implant during earlier phases of heart failure—when a patient’s leaky mitral valve is still considered to be functional—could lead to ...

The Everest II Clinical Trial is a study comparing nonsurgical repair for severe mitral valve regurgitation with conventional surgery. The MitraClip procedure is performed in a cardiac catheterization ...

ABBOTT PARK, Ill., Sept. 21, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark for its fourth-generation MitraClip™ Transcatheter Mitral Valve Repair System, the leading ...